A pilot study on efficacy and safety of 100 ug start dose wasp venom immunotherapy (VIT)

Completed

• Conditions: insect venom hypersensitivity; wasp venom allergy; 10001708

• Registration Number: NL-OMON38607
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- A positive history of a systemic response grade II/III/IVa after vespid sting
- Specific serum IgE > 0.7 kU/
- Positive intracutaneous skin test for vespid venom ( at <= 1 µg/ml)

Exclusion Criteria

- A positive history of a systemic response grade IVb according to Müller after a vespid sting
- Age under 18 years or above 65 years
- Severe cardiopulmonary disease (clinical evidence of congestive heart failure, coronary disease or severe hypertension)
- Insufficiently controlled asthma, especially if FEV1 is 70% of predicted.
- Conditions that influence the immune system (immune deficiencies, malignancy, auto-immune diseases)
- Severe kidney failure
- Interfering medication with the outcome or recovery from a systemic reaction (β-blockers and immunosuppressive drugs)
- Allergy to auxiliary matter in Pharmalgen® Vespula spp.
- Pregnancy
- Mastocytosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>zie protocol</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>zie protocol</p><br>